China rejects Gilead’s patent for $1,000-a-day drug By: MarketWatch June 19, 2015 at 12:40 PM EDT China has rejected a patent application for Gilead’s controversial hepatitis C drug, Sovaldi, which costs $1,000 a day. Read More >> Related Stocks: Gilead Sciences